CureDuchenne and Baebies Team Up in New Diagnostic Effort

Backed by more than two decades of experience as an entrepreneur and health care executive, Jeffrey Goffman has served as the CEO and chairman of Integrated Oncology Network, LLC, since co-founding the company in 2009. In addition, Jeffrey Goffman is the board chairman for CureDuchenne, a charitable organization devoted to supporting those with Duchenne muscular dystrophy.

In October 2018, CureDuchenne announced a new joint initiative with Baebies, a company specializing in newborn screening and testing technology for pediatric patients. Through the partnership, Baebies will incorporate Duchenne muscular dystrophy into the list of potential conditions for which it screens in newborns. Duchenne most commonly affects boys and typically manifests between three and five years of age.

By receiving an early diagnosis, parents will be able to be proactive in the treatment of the disease in their children, while also providing researchers with critical information about how Duchenne develops and symptoms to look for in newborns and infants. To learn more about CureDuchenne and its fight against the disease, visit cureduchenne.org.